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                                     INTRODUCTION 
 Stroke is one of the most common causes of morbidity and mortality.  It causes 
long-term disability to most of the patients1. Apart from the known risk factors like 
hypertension, diabetes and dyslipidemia newer risk factors like homocysteine, 
fibrinogen and lipoprotein(a) are emerging! 
Lipoprotein(a) has been implicated recently to the occurrence of vascular 
events (coronary, cerebral and peripheral)2 
Several case control and cross sectional studies have reported higher levels of 
lipoprotein(a) in stroke and transient ischemic attacks.3-7 
Existing  prospective trials have failed to demonstrate an association of 
lipoprotein(a) and the future risk of stroke.  So the results are contradictory and it 
lacks consistency8-13. 
Indian studies relating lipoprotein(a) to stroke are lacking. Hence this study 
was conducted primarily to find out the lipoprotein(a) levels in young ischemic 
stroke and to analyse it. 
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AIMS OF THE STUDY 
 
1. To study the levels of lipoprotein(a) in young ischemic stroke 
 (40 years or less). 
2. To assess whether lipoprotein(a) is an independent risk factor for ischemic 
stroke. 
 
3. To compare levels of lipoprotein(a) between control and diseased. 
4. To assess variation of lipoprotein(a) levels with age. 
5. Correlation of lipoprotein(a) levels between men and women. 
6. Relationship of lipoprotein(a) levels to recurrent ischemic stroke. 
7. Comparison of our study results with other Indian and foreign study results. 
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EPIDEMIOLOGY OF STROKE 
          Stroke is a heterogenous syndrome caused by many disease mechanisms, 
all of which result in disruption of cerebral blood flow and subsequent tissue 
damage. It is the third leading cause of death and one of the commonest cause 
of disability in adults.14
                    In 2001, stroke accounted for 5.5 million deaths worldwide. It is 
equivalent to 9.6% of all death. Developing countries accounted for two- third 
of the deaths. 
        The average age of patients with stroke is 15 years younger in developing 
countries.15
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                     The death rates due to stroke is higher in male than in female. But in 
population aged 65 years and over, when most strokes occur, the death rate in 
women outnumber men. 
         The reason for this apparent contradiction is that women outlive men and 
that age is an important risk factor for stroke16. [Department of Health and 
Human Services, national centre for health statistics]. 
 
              The limited data available indicate that stroke occurring in young people 
is more often atherothrombotic in origin in developing countries, 17-19 in 
contrast to developed countries where arterial dissection and cardio embolic 
etiology predominate.20-22
              Total stroke incidence rate increases exponentially with age for both 
men and women. 
               The prevalence rate for cerebrovascular diseases vary throughout the 
world from 1.43-20/1000. The highest rates were recorded in Japan (20/1000).  
ASIAN PERSPECTIVE: CHANGING TRENDS 
 Earlier studies noted that Asians have a lower rate of coronary heart disease 
and higher prevalence of stroke.23 Among the Asians, the death from stroke 
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outnumber that of coronary heart disease by three times. The age standardized, gender 
specific stroke mortality rate was 44 to 102.6/1,00,000 for Asian males, compared 
with only 19.3 for Australian white males.23
The disparity between stroke and coronary heart disease (CHD) incidence rates 
is usually attributed to high prevalence of hypertension and low levels of blood lipids 
among the Orientals. The above epidemiological data among Asians is based on the 
surveys carried out in Chinese population. 
          There is a shift in this trend for the past two decades. By 1985, coronary heart 
disease (CHD) became commoner than stroke as the cause of death among Japanese. 
This mortality profile parallels the change in the dietary habit. The current Japanese 
diet have increased animal fat and reduction in the amount of common salt. 
INCIDENCE OF STROKE IN INDIA 
Conducting an epidemiological survey in a developing populated country like 
India is a daunting task.  According to the Asian Acute Stroke Advisory panel, India is 
still ranked among the countries where the information on stroke is minimal.  The 
Global Burden of Disease study 1997, reported 9.4 million deaths in India, out of 
which 619,000 were from stroke. Disability adjusted life years (DALY) for stroke was 
calculated as 28.5 million. It was 6 times more than malaria24. 
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Several population-based surveys on stroke were conducted from different 
parts of India, primarily to determine the cross sectional prevalence. [Reference, 
Table: A] 
Very few surveys in India have determined the Annual Incidence Rate (AIR) of 
stroke. [Table: B]  
All these surveys were underestimates because only the stroke survivors and 
not the stroke death cases were included. 
 
           Stroke related mortality is hugely under estimated because medical certification 
of cause of death is not followed. Only 13.5% of all deaths in India were medically 
certified23 in 1994. It was estimated that stroke represented 1.2% of total deaths in the 
country, when all ages were included. The proportion of stroke death increased with 
age, and in the oldest group (of greater than 70 years of age) it represented 2.4% of all 
deaths.  
According to the reports available, the prevalence rates of stroke for 
North India (Kashmir) being 143/1,00,000 
East India (Assam)                270/1,00,000 
West India (Mumbai)            245/1,00,000 
South India (Vellore)            64/1,00,000. 
 
     
7 
 
Average range being 90-220 /1, 00,000 persons.  This report does not take Transient 
Ischemic Attacks (TIA’S) into account. 
          
            The Indian Collaborative Acute Stroke Study (ICASS) was a prospective 
multicentric study on unselected CT confirmed cases of acute stroke (less than 
72hours) admitted to major university hospitals in India24. (Chandigarh, New Delhi, 
Mumbai, Pune, Bangalore, Chennai, Hyderabad.).   
            
              During the study period between 2002-2004, reliable information was 
collected in 2162 acute stroke cases. It was reported that the incidence of stroke was 
rising with advancing age – the maximum being in the age group of 41-70years. 
Ischemic strokes accounted for 77%, hemorrhagic strokes 22 % and unspecified 
account for 1 %.       
RISK FACTORS FOR STROKE   
MAJOR  
• Hypertension 
• Heart disease 
• Cigarette smoking 
• Transient ischemic attack. 
SECONDARY 
• Increased serum cholesterol/lipids  
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• Physical inactivity 
• Obesity. 
 
EVOLVING RISK FACTORS 
• Lipoprotein(a) 
• Apoprotein ‘E’ allele 
• Serum homocysteine 
• Factor 5 Leiden mutation. 
LESS WELL DOCUMENTED 
• Excessive alcohol intake 
• Drug abuse 
• Acute infections. 
 
The single most important risk factor for stroke is age of the individual .Of all the 
controllable risk factors, hypertension is the most important [Wolf PA, et al, 1992]. 
Hypertension accelerates the atherothrombotic cerebral infarction.  It also increases 
the risk of hemorrhage by promoting cerebral vascular microaneurysms.  (Charcot 
Bouchard aneurysms). [Harrison’s Principles of Internal Medicine] 
 
NON-MODIFIABLE RISK FACTORS IN STROKE 
 
• Age  
• Male sex 
• Race  
• Diabetes mellitus 
• Prior stroke / Transient Ischemic Attacks 
• Family history of stroke  
• Asymptomatic carotid bruit. 
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MECHANISMS OF STROKE  
Stroke is classified broadly into, 
a) Ischemic stroke  
b) Hemorrhagic stroke.   
Ischemic stroke comprises 80% of the incident strokes and hemorrhagic stroke 
makes up the remaining 20%. 
 
Ischemic strokes can be classified into,  
1. Embolic stroke 
2. Thrombotic stroke 
3. Lacunar stroke 
4. Watershed infarcts.  
EMBOLIC STROKE 
Embolic may be either cardiac or arterial in origin. Cardiac sources include 
atrial fibrillation, recent myocardial infarction, prosthetic valves, native valvular 
disease, endocarditis, mural thrombi, dilated cardiomyopathy or patent foramen ovale.                
Arterial sources are atherothrombotic or cholesterol emboli that develop in the arch of 
aorta and in extracranial arteries. 
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THROMBOTIC STROKES 
Thrombotic stroke include, 
a) Large vessel stroke 
b) Small vessel (or) lacunar stroke. 
They are due to insitu occlusions on atherosclerotic lesion in the carotid, 
vertebrobasilar and cerebral arteries. 
 
Thrombogenic factors include, 
a) Injury to and loss of endothelial cells. This exposes subendothelium 
resulting in platelet activation 
b) Activation of the clotting cascade 
c) Inhibition of fibrinolysis 
d) Stasis of blood. 
LACUNAR STROKE 
Lacunar stroke represent 20% of all ischemic strokes. They occur when the 
penetrating branches of the middle cerebral artery, the lenticulostriate arteries, or the 
penetrating branches of the circle of Willis, vertebral artery or basilar artery become 
occluded.  
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Causes of lacunar infarcts are,  
Microatheroma 
 Lipohyalinosis 
Fibrinoid necrosis  
Secondary to hypertension or vasculitis 
Hyaline arteriosclerosis  
Amyloid angiopathy.  
WATERSHED INFARCTS 
They are also called as border zone infarcts, develop from relative hypo -
perfusion in the most distal arterial territories and produce bilateral symptoms. They 
occur in perioperative conditions or in situations of prolonged hypotension. 
YOUNG STROKE  
 Though cerebral infarction is predominantly a disease of the senescence, its 
occurrence in younger age groups is not rare (Thorvalsden et al., 1995).  Stroke in the 
young is particularly tragic because of the potential to create a long-term burden for 
the victims, their families and the community (You et al., 1997). 
 The hospital admission rates often vary from country to country.  Regardless of 
the percentage of cases occurring among young individuals, most authors today agree 
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that among victims of cerebral infarction, young people are not rare (Bogousslavsky 
and Pierre 1992, Bevan et al., 1990 and Rouhaet et al., 1993). 
 The etiological investigations of young patients with cerebral infarction have 
identified a large number of possible causes (Bausal and Sood 1986, Biller et al., 1986 
and Adams., et al., 1986).  Inspite of extensive investigations, in 16 % of such patients 
a clear underlying cause is not found (Adams et al., 1995 and Neto et al., 1996). 
The prevalence and risk factors involved in young stroke vary from the older 
individuals. 20-30 % of the hospital stroke populations fall below the age group of 
40years.  
In persons aged 20-44 years in a U.S study [1993-1997], the Annual Age-
Adjusted Stroke Incidence Rate was 23 per 100,000 persons per year. [Stroke V: 33 
12/02 P2789]. 
 
Ischemic stroke occurring in young Indians could well be a manifestation of 
accelerated cerebrovascular atherosclerosis. The traditional risk factors like 
hypertension, diabetes and smoking along with certain other evolving risk factors play 
a role in the pathogenesis of young ischemic stroke.  
 
In 1996, Neto et al., studied the possible causes of cerebral infarction in 
patients aged fifteen to forty years.   
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They classified the patients into five subgroups namely, 
1. Large artery atherosclerosis 
2. Small vessel occlusion (or lacunes) 
3. Cardioembolism 
4. Stroke of other determined cause 
5. Stroke of undetermined cause. 
LARGE ARTERY ATHEROSCLEROSIS 
 In this group the recognised risk factors like,  
1. Arterial hypertension 
2. Smoking  
3. Left ventricle hypertrophy 
4. Heavy alcohol consumption 
5. Hypercholesterolemia played the causative role. 
According to investigators, the number of atherothrombotic infarctions is small 
among young patients (Alvarez et al., 1989 and Bogousslavsky and Pierre 1992). 
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SMALL VESSEL OCCLUSION  
 The risk factors for small vessel occlusion were, 
1. Hypertension 
2. Diabetes mellitus 
3. Left ventricular hypertrophy. 
 
 
 
CARDIOEMBOLISM 
 The source of embolism detected were, 
1. Synthetic  prosthesis 
2. Mitral valve prolapse 
3. Dilated cardiomyopathy 
4. Apical aneurysm 
5. Double mitral lesion 
6. Segmental hypokinesia 
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7. Recent myocardial infarction 
8. Aseptic endocarditis. 
STROKE OF OTHER DETERMINED CAUSES 
This group included more than 15 different causes of cerebral infarction.  
These cases include, 
a) Protein C deficiency 
b) Sickle cell anaemia 
c) Protein S deficiency 
d) Arterial dissection 
e) Moya Moya syndrome 
f) Vasculitis 
g) Systemic lupus erythematous 
h) Primary antiphospholipid syndrome 
i) Migraine 
j) Use of oral contraceptive pills. 
The fifth group included patients in whom the etiology of cerebral infarction 
was undetermined despite an extensive workup. 
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Emerging risk factors like lipoprotein(a), homocysteine and fibrinogen could 
constitute the fifth group.  Other causes include Mitochondrial Encephalomyopathy, 
Lactic Acidosis and Stroke like Episodes (MELAS) and Cerebral Autosomal 
Dominant Arteriopathy with Subcortical Infarct and Leucoencephalopathy 
(CADASIL).     
   
 
 
 
BIOLOGY OF LIPOPROTEIN(a) 
  Lipoprotein(a) was described by Berg in 1963.25 The role of lipoprotein(a) 
gained clinical significance after 1987, when Mclean et al, suggested the structural 
homology between apoprotein(a) and plasminogen.26 
STRUCTURE OF LIPOPROTEIN(a) 
 Lipoprotein(a) is a low density lipoprotein (LDL)) like molecule.  It consists 
of apoprotein B-100 particle attached by a disulphide bridge to apoprotein (a).27 
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 Apoprotein(a) is a member of a family of “Kringle”, containing proteins such 
as plasminogen, tissue Plasminogen Activator (tPA), prothrombin, factor XII and 
Macrophage Stimulating Factor (MSF).28,29 
 Lipoprotein(a) shares a high degree of sequence identity with plasminogen.30 
It competitively binds to the plasminogen receptor, thus reducing the activity of 
plasminogen. 
 The apoprotein gene is highly polymorphic, more than thirty four (34) different 
sized alleles have been identified.31 Molecular weight ranges from 187-648 kilodalton 
(KDa).32,33 
 Plasma lipoprotein(a) concentration varies inversely with the size of 
apoprotein isoform.34 Smaller isoforms are usually associated with higher total 
lipoprotein(a) levels and a higher risk of atherogenicity.35 
 The most important factor in determining lipoprotein(a) levels is apoprotein(a)  
gene locus.  It accounts for 90% of variation of plasma lipoprotein(a) levels.36 
 Apoprotein(a) consist of a series of tandemly repeated modules known as 
kringles, that are commonly found in many proteins involved in fibrinolytic and 
coagulation cascades such as plasminogen and thrombin respectively.26 
 Specifically, apoprotein(a) contains multiple tandem repeats of domain similar 
to plasminogen kringle IV followed by sequences similar to kringle V and protease 
domain of plasminogen. 
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 Kringles are triple looped cysteine linked amino acid domains. They are held 
together by the formation of three internal disulphide bonds.  Ten types of kringle IV 
(KIV1-10) like domains are found in apoprotein(a). 
Structure of lipoprotein(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUMAN PLASMINOGEN 
Plasminogen is the precursor of the anticoagulant protein plasmin.  A single 
human plasminogen peptide chain consists of 791 amino acid residues and two 
carbohydrates attached to the peptide chain by the presence of disulphide bonds. 
Plasminogen’s structure is divided into a contiguous series of five homologous regions 
called Kringles.  Human plasminogen consists of an amino terminal peptide, five 
kringle modules and a protease domain. 
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The apoprotein(a) gene contains a single protease domain that is 94% identical 
to the protease domain of the plasminogen gene.  It also contains two plasminogen like 
kringle domains one of them homologous to kringle 4 and the other kringle 5. 
 
 
 
DIFFERENCES BETWEEN APOPROTEIN(a) AND PLASMINOGEN 
1. Unlike plasminogen, apoprotein(a) cannot be converted to an active protease by 
tissue plasminogen activator, streptokinase or urokinase.  This is due to single 
amino acid substitution in apoprotein(a) that makes it resistant to the activity of 
these proteases. 
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2. Presence of one single unpaired cysteine residue of apoprotein(a) to facilitate 
binding to apoprotein B-100. Lipoprotein(a) is very rich in carbohydrate 
containing 28.1% carbohydrate by weight. 
 
 
 
GENETICS, RACE AND NORMAL LEVEL 
Levels of lipoprotein(a) are largely genetically determined, does not show 
significant variation with age and it varies with race and ethinicity.37  
At birth, lipoprotein(a) levels are reported to be low. In newborns, it is not 
related to gender or race as in adults. Serum lipoprotein(a) concentration increases 
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during first year of life and reaches the adult concentration by the second year.38 
Thereafter no variation with age occurs. Levels are higher in Asians and Africans 
when compared to white population in Framinhgham study.  Levels above 30 mg/dl 
are generally considered as elevated. 
MODULATION OF PLASMA LIPOPROTEIN(a) CONCENTRATION  
There was no significant correlation of lipoprotein(a) levels with age, height, 
Body Mass Index, total cholesterol, high density lipoprotein(HDL) or low density 
lipoprotein(LDL)39.  
The level of lipoprotein(a) is increased in diabetes mellitus, chronic renal 
failure, nephrotic syndrome, malignancy, menopause, and hypothyroidism. 
Lipoprotein(a) levels is decreased in liver cell failure and hyperthyroidism. Diet, 
weight loss and exercise have no effect on lipoprotein(a) levels.               
 
Smaller or no difference at all in lipoprotein concentration were noted between 
males and females in different adult population. Mean levels of lipoprotein(a) in a 
normal population were 14 mg/dl for men and 15mg/dl for women as given by recent 
Framingham Study. 
SYNTHESIS AND METABOLISM OF LIPOPROTEIN(a) 
The dominant effect on the serum concentration of  lipoprotein(a) is exerted 
by the rate of hepatic secretion40. This is consistent with the fact that after 
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heterologous liver transplantation, apoprotein(a) phenotype changes to that of the 
donor41. So, patients with liver disease and alcohol abuse will have low lipoprotein(a) 
levels42.  
The most important factor in determining the lipoprotein(a) levels is 
apoprotein(a) gene locus.  
 The assembly of lipoprotein(a) is extracellular.43,44 Newly synthesised     
apoprotein(a) binds to hepatocyte cell surface via its kringle domains.45 From this 
location, it is captured by apoprotein B and released from the cell as lipoprotein 
particle.  The cell surface of association of apoprotein(a) is important to prevent the 
release of  apoprotein(a) into plasma where it may participate in potentially 
detrimental associations with other cell surfaces.46 
   
            The mechanism of lipoprotein(a) clearance from the circulation is much less 
well defined. Previously, lipoprotein(a) was thought to be degraded through the low 
density lipoprotein(LDL) receptor pathway.  However, two recent studies have shown 
that this is not the primary pathway.47 
Synder et al., showed that the binding and degradation of lipoprotein(a) by the 
low density lipoprotein(LDL) - receptor pathway in human hepatocytes, macrophages 
and fibroblast was only 10 - 30%.48 Other pathways involved in lipoprotein(a) 
catabolism are less clear. 
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Certain in vitro studies have demonstrated that non-low density 
lipoprotein(LDL) receptor pathways contribute towards lipoprotein(a) catabolism.48,49 
Lipoprotein lipase may facilitate some of its uptake.  A receptor for lipoprotein(a) has 
been demonstrated in human macrophages and glycoprotein II b on platelets. 50,51  The 
role of such pathways in the clearance of lipoprotein(a) from plasma is under study.    
LIPOPROTEIN (a) IN CORONARY HEART DISEASE 
              Many prospective studies were conducted to find out the association of 
lipoprotein(a) and coronary heart disease.52  It was noted that raised lipoprotein(a) 
levels were associated with the presence and severity of coronary heart disease.53 
                   Children of parents with premature heart disease had higher lipoprotein(a) 
levels than children of healthy parents54. 
              Lipoprotein(a) levels in restenosis is under extensive study and till date, it 
has yielded only conflicting results.55 Studies by Daida et al, noted a much lower 
restenosis rates in patients, whose lipoprotein(a) levels are markedly reduced by the 
technique of  apheresis.56Bruegman et al 57 and Molliterno et al,58 suggest that 
lipoprotein(a) levels play an important role in spontaneous thrombolysis.
LIPOPROTEIN(a) AND DIABETES MELLITUS 
           Variation of lipoprotein(a) levels in diabetic individuals was studied by 
various research teams. Conclusions appear to vary depending on the type of diabetes.  
A study on 415 children aged 13-14 years with type 1 DM by Salzer et al, showed 
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significantly higher levels of lipoprotein(a) in diabetic children59 compared with 
normal children.  Pubertal and post pubertal patients had higher levels compared with 
control subjects. This observation gave way to suggestions that a rise in 
lipoprotein(a) occur during puberty in type 1 DM.60 
Majority of studies in type 2 DM failed to show an increase in levels of 
lipoprotein(a). It is reported that patients with type 2 DM have lower, 61, 62 higher63, 64 
or similar65-69 lipoprotein(a) levels compared with non-diabetic subjects.   No 
significant relationship between lipoprotein(a) levels and glycemic control was noted 
in the group of type 2 DM .70,71
 
 
 
 
LIPOPROTEIN(a) AND KIDNEY 
Markedly elevated lipoprotein(a) levels have been described in all kinds of 
renal disease and their treatment modalities. On an average, lipoprotein(a) levels are 
elevated six times in nephrotic syndrome72, two to three fold in patients receiving 
hemodialysis or peritoneal dialysis as compared to healthy controls.73,74
              It was suggested that elevation of lipoprotein(a) occur early in renal failure, 
or alternatively, elevated lipoprotein(a) levels may promote progression to chronic 
renal failure.75 Renal transplantation in end stage renal failure is accompanied by a 
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significant decrease in lipoprotein(a).75  Irish et al found that the type of treatment of 
chronic renal failure influences the plasma level of lipoprotein(a).   The patients on 
continuous ambulatory peritoneal dialysis showed significant increase in 
lipoprotein(a), when compared to hemodialysis.                    
 
DRUGS AND LIPOPROTEIN (a) 
Lipid lowering drugs like statins and resins does not have any effect on 
lipoprotein(a). Estrogen replacement therapy in post menopausal women lowers 
lipoprotein(a).76,77 High dose (3-4 gm/day) niacin has been reported to lower 
lipoprotein(a) by 35-50%.78  Linus Pauling suggested that Vitamin C does lower 
lipoprotein(a) levels.  Fenofibrate has shown some lipoprotein(a) lowering effect in 
recent studies by 14%.  There is no larger scale trial available supporting this study.79
LIPOPROTEIN(a) - ASSOCIATION WITH OTHER THROMBOTIC RISK 
FACTORS 
LIPOPROTEIN(a) AND FIBRINOGEN 
Serum lipoprotein(a) levels correlate significantly with plasma fibrinogen 
levels in some studies, but not in all.80,81 Platelet activity is enhanced by fibrinogen 
and raised plasma fibrinogen concentrations are predictors of vascular events.82,83 
There is a strong evidence that fibrinogen is an independent risk factor for 
ischemic atherothrombotic stroke.84It is also associated with increased risk of 
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recurrent vascular events.85 Fibric acid derivatives used to reduce circulating 
concentrations of lipoprotein(a) also reduce levels of serum fibrinogen.86 
LIPOPROTEIN(a) AND HOMOCYSTEINE 
A moderate increase in circulating homocysteine concentration is associated 
with an increased risk of atherosclerosis and venous thrombosis.87,88  Concomitant rise 
of lipoprotein(a) and homocysteine has  shown to increase the risk of vascular 
events.89 
 Both lipoprotein(a) and homocysteine exhibit effects on platelets, coagulation 
and fibrinolysis. Homocysteine increase platelet aggregability and promote 
vasoconstriction through thromboxane A2 release.90 Homocysteine is a strong 
predictor of ischemic stroke.91 The levels of homocysteine is influenced by renal 
function and vitamin B12 status. 92 
Homocysteine, lipoprotein(a) and fibrinogen interact together to promote 
atherogenesis.93 The clustering of all the three increases the risk of vascular events. 
Epidemiological studies indicate that dyslipidemia + raised lipoprotein(a) and 
dyslipidemia + raised fibrinogen combination increase the risk of vascular 
events.94,95,96 
LIPOPROTEIN(a) AND STROKE 
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The possibility of lipoprotein(a) as a risk factor for ischemic stroke has been 
assessed in several case control and retrospective studies.   The results differ and are 
not conclusive.    
STUDIES SUPPORTING LIPOPROTEIN(a) AS A RISK FACTOR FOR STROKE 
 In a case control study [Jurgens G et al, lipoprotein(a) in ischemic 
cerebrovascular disease - a new approach to the assessment of risk for stroke. 
Neurology 1987], serum lipoprotein(a) levels were significantly (p < 0.001) higher in 
patients with ischemic stroke compared with healthy individuals.97 
Lindgren et al, determined lipid variables in 131 patients six months after 
stroke.98 These patients had higher triglycerides and lipoprotein(a) levels and lower 
total cholesterol, low-density lipoprotein and high-density lipoprotein concentrations 
compared with controls.  
In a study conducted in 45 patients with  stroke (younger than 55 years) and 
their first degree relatives by Vavernova et al, lipoprotein(a)  levels were reported to 
be genetically conditioned in patients with ischemic stroke.99 
Jurgens et al, determined lipoprotein(a) and apoprotein phenotypes in a 
consecutive series of 265 patients with ischemic stroke in comparison with 288 
controls.100They suggested that raised lipoprotein(a) concentrations comprise a 
primary risk associated with the presence of this disease.  
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Van Kooten and colleagues101 assessed lipoprotein(a) concentrations in 151 
consecutive patients admitted because of acute cerebral ischemia.  They found that in 
about one third of patients lipoprotein(a) levels were significantly raised.  
Peynet et al, evaluated the lipoprotein(a) concentrations and apo(a) isoform 
size in 90 young individuals (mean age 37.4) with acute cerebral ischemia compared 
with age and sex matched individuals. They showed that serum lipoprotein levels 
were significantly (p<0.009) elevated in patients with stroke.102 
Nagayama et al, in a case control study, 103 investigated lipoprotein(a) levels in 
patients after a period of 27 months since their stroke . They concluded that 
lipoprotein(a) was a crucial and independent risk factor for ischemic stroke. 
 In the Atherosclerosis Risk In Communities (ARIC) study, 104 the association 
of lipoprotein(a) with stroke was investigated in 15,160 participants. In this study, 
lipoprotein(a) was an independent risk factor for stroke and TIA. 
 
 
 
 
STUDIES NOT SUPPORTING LIPOPROTEIN(a) AS A RISK FACTOR FOR 
STROKE 
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Hachinski et al, 105 determined lipid variables, including lipoprotein(a) in 80 
patients with stroke or Transient Ischemic Attacks(TIA). Increased low density 
lipoprotein(LDL) and triglyceride(TG) concentrations correlated with 
atherothrombotic stroke risk, whereas no statistical significance was noted with 
lipoprotein(a). 
In a study conducted by Glades et al, 106 no association between baseline 
plasma lipoprotein(a) levels and future ischemic cerebral infarct was noted.  
In a prospective study in Finland, no association was found between 
lipoprotein(a) levels and atherosclerotic disease.107
In a cohort study, 14,916 persons were followed prospectively for a period of 
7.5 years.  No association between baseline plasma concentration of lipoprotein(a) 
and future risk of  thromboembolic stroke was found. 108  
 
 
 
 
 
 
LIPOPROTEIN(a)  PATHOPHYSIOLOGY AS AN 
 ATHEROTHROMBOGENIC FACTOR 
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 ATHEROGENICITY 
a. Lipoprotein(a) plays an important role in the initiation, progression and 
subsequent rupture of atherosclerotic plaque.109 
b. The accumulation of lipoprotein(a) molecules has been demonstrated in the 
arterial walls of human coronary and cerebral vessels.110 
c. Apoprotein(a) has a tendency to bind to connective tissue elements like 
proteoglycans, glycosaminoglycans and fibronectin.111  This binding is 
promoted by lipoprotein(a) lipase or sphingomyelinase.112 
d. Lipoprotein(a) particles undergo oxidative modification and scavenger 
receptor uptake, leading to intracellular accumulation and foam cell formation 
in vascular endothelium.113,114 
e. The process of increased atherogenicity of lipoprotein(a) is similar to the role 
played by low density lipoproteins(LDL) in the formation of atherosclerotic 
plaque. 
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THROMBOGENICITY 
 
a. The apoprotein moiety of lipoprotein(a) bears a structural homology to 
plasminogen. 
b. Lipoprotein(a) competes with plasminogen for its receptors on endothelial 
cells.  This reduces the activity of plasminogen significantly, resulting in 
diminished plasmin formation.  This delays clot lysis and favours 
thrombosis.115 
c. Lipoprotein(a) binds to immobilized fibrinogen and fibrin resulting in 
inhibition of plasminogen binding to these substrates.  The high affinity of 
lipoprotein(a) to fibrin is the causes for its co-localisation in atherosclerotic 
plaque.116 
d. Lipoprotein(a) enhances the synthesis of Plasminogen Activator Inhibitor   
(PAI-1) by endothelial cells.117 This property of lipoprotein(a) contributes to 
its anti-fibrinolytic activity. 
e. Lipoprotein(a) displaces plasminogen from the surface of macrophages in 
atherosclerotic plaques and it reduces the activation of latent Transforming 
Growth Factor β (TGF- β).  In the absence of activated TGF- β, cytokines 
induces smooth muscle proliferation.118 
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ENDOTHELIAL DYSFUNCTION   
High levels of lipoprotein(a) is also associated with endothelial dysfunction.  
This endothelial dysfunction is enhanced by lipid deposition in vessel walls, inhibiting 
fibrinolysis and modulating smooth muscle proliferation.119 
 
ATHEROSCLEROSIS IN INTRACRANIAL ARTERIES 
        Intracranial arteries are relatively resistant to cholesterol related endothelial 
damage.120 
a. Studies on human necropsy has shown that atherosclerotic changes in cerebral 
arteries make their appearance 20 years later than in coronary arteries.121
b. Recent study by Landray et al, in stroke patients underlined low density 
lipoproteins( (LDL) score to have a borderline significance.122
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c. In another experimental model by Wullian et al, high lipoprotein(a) levels were 
associated with occlusive arterial thrombosis in intracranial vessels and may also 
causes permanent cessation of flow.123
d. Analysis of damaged arterial segments indicated incorporation of lipoprotein(a) 
into adventitia, media and intima.123
e. Watts and colleagues et al showed raised lipoprotein(a) concentrations were a 
significant determitant of the carotid atherosclerosis.124      
f. Endothelial dependent vasomotor tone is also related to lipoprotein(a) levels but 
its clinical implications are not yet determined (Delanty etal). 125        
 
MATERIALS AND METHODS 
The study was conducted in Thanjavur Medical College Hospital, Thanjavur, 
Tamilnadu.  The study was conducted in the Department Of Internal Medicine. The 
study period extended between June 2007 and October 2008.  It was a carefully 
selected study population of stroke, purely ischemic in patients aged forty years or 
less, without any other identifiable risk factors.  The patients were selected on the 
basis of inclusion and exclusion criteria.  In all those patients, lipoprotein(a) was 
estimated and discussed later.  The study included both sexes.  
The control population included similar age group in both sexes and without 
any identifiable risk factor. The control group was selected from the inpatient 
population of medical wards.  
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  A total number of 25 cases have satisfied the criteria for the study group. 
 
INCLUSION CRITERIA 
Two absolute inclusion criteria are  
1) Age forty years or less 
2) CT scan showing purely ischemic infarcts. 
 Patients of both sexes, with family history of stroke and history of recurrent 
stroke were also included in the study.    
EXCLUSION CRITERIA 
1. Age greater than 40 years  
2. CT brain showing hemorrhage 
3. Hypertensive ( BP >140/90mm Hg ) 
4. Diabetics 
5. Valvular heart disease 
6. ECG / ECHO evidence of CAHD (Coronary Artery Heart Disease) 
7. VDRL - reactive 
8. HIV - reactive 
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9. Malignancy  
10. Lipid lowering drugs 
11. Rheumatoid arthritis 
12. Renal failure  
13. Diabetic nephropathy 
14. Nephrotic syndrome 
15. Liver cell disease 
16. Thyroid dysfunction (hypothyroidism / hyperthyroidism). 
 
              A proforma was drafted including the details about the presenting illness and 
specifically related to known risk factors and factors that can elevate lipoprotein(a).  
History of recurrent stroke, Transient Ischemic Attacks and history of stroke in family 
members were enlisted. 
 
 All patients were subjected to routine physical examination. Body Mass Index 
(BMI) was calculated for every person.       
 
CT scan brain and repeat CT scan (if needed) was done and the reports were 
included.  The results of VDRL and HIV were entered. 
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Routine blood investigations like complete hemogram, blood sugar (random 
and fasting), blood urea, serum creatinine, erythrocyte sedimentation rate, packed cell 
volume and complete urine examination were done. 
The levels of lipoprotein(a) was entered in the proforma. 
 
 
 
 
 
 
METHODOLOGY 
Lipoprotein(a) Estimation 
The sample was withdrawn after a period of over night fasting. 5ml of venous blood 
was collected in a sterile glass tube.  The blood was allowed to clot, centrifuged and 
analysed for lipoprotein(a) levels using NEPHELOMETRY method. 
  NEPHELOMETRY 
Nephelometry is defined as the detection of light energy scattered towards a 
detector that is not in the direct path of the transmitted light. Common nephelometers 
available measure scattered light at right angles to the incident light. Some of them 
have detectors placed at angles of 60◦-70◦. 
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This enables to take advantage of the increased forward scatter intensity caused 
by light scattering from large particles. The amount of light scattered is proportional to 
the concentration of antigen or antibody in the solution. 
Nephelometry is one the most commonly used technology for protein assays 
such as apolipoproteins, lipoprotein(a), C-reactive protein, rheumatoid factor, anti- 
Streptolysin O, C3, C4, immunoglobulins etc., Other method commonly used is 
turbidimetry. 
Nephelometry methods are more sensitive than turbidimetry with a detection of 
approximately 10µg/ml, whereas detection limit of turbidimetry is 20-30µg/ml. 
Nephelometry shows a slightly better detection limit in lipemic samples. 
RESULTS AND ANALYSIS 
 The study population included 25 young ischemic stroke patients with 23 males 
and 2 females matched with 25 age and sex matched controls.  All patients were 
admitted to medical wards and discharged after an average period of 5 days. 
AGE INCIDENCE  
Table 1 
Age in years 16-20 21-25 26-30 31-35 36-40 
No. of cases 2 2 5 6 10 
Percentage 8% 8% 20% 24% 40% 
Fig 1  
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AGE INCIDENCE-TOTAL POPULATION 
8%
8%
20%
24%
40% 16-20
21-25
26-30
31-35
36-40
 
                                            SEX INCIDENCE  
 
Our study group included twenty three males and two females. 
 
Table 2  
SEX NO. OF CASES PERCENTAGE 
MALES 23 92% 
FEMALES 2 8% 
 
Fig 2  
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SEX INCIDENCE - TOTAL POPULATION 
23
2 92% 8%0
5
10
15
20
25
NO OF CASES PERCENTAGE
MALES
FEMALES
 
 
LIPOPROTEIN(a) LEVELS ACCORDING TO AGE IN STUDY GROUP 
 
Table 3 
AGE(YEARS) 
NO. OF 
PERSONS 
LIPOPROTEIN(a) 
 >30 mg / dl. 
PERCENTAGE
16-20 2 1 50% 
21-25 2 1 50% 
26-30 5 4 80% 
31-35 6 5 83% 
36-40 10 9 90% 
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Fig 3  
STUDY GROUP 
 
2
1
2
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4
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LIPOPROTEIN(a)   LEVELS   ACCORDING   TO   AGE   IN 
CONTROL GROUP 
Table 4 
AGE 
(YEARS) 
NO OF PERSONS LIPOPROTEIN(a)        
> 30 mg/dl. 
PERCENTAGE
16-20 2 - - 
21-25 2 - - 
26-30 5 1 20% 
31-35 6 - - 
36-40 10 2 20% 
Fig 4 
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CONTROL GROUP 
 
2
2
5
6
10
1
2
20%0
5
10
15
20
25
NO OF PERSONS LIPOPROTEIN(A)     
> 30 mg/ dl.
PERCENTAGE
36-40
31-35
26-30
21-25
16-20
 
 
 
 
 
 
LIP
OPROTEIN(a) LEVELS  IN CONTROL AND STUDY POPULATION 
 
Table 5 
LIPOPROTEIN(a) 
NO OF CASES IN STUDY 
GROUP 
CONTROL 
GROUP 
< 30 mg / dl 5 22 
>30 mg / dl 20 3 
Fig 5 
STUDY AND CONTROL GROUP 
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DISTRIBUTION   OF PATIENTS ACCORDING TO LIPOPROTEIN(a) 
LEVELS IN STUDY GROUP 
  
Table 6 
LIPOPROTEIN(a) 
mg/dl 
< 30 30-59 60-99 >100  
NO OF PERSONS IN 
STUDY GROUP 
5 15 3 2 
Fig 6  
STUDY GROUP 
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DISTRIBUTION OF PATIENTS ACCORDING TO LIPOPROTEIN(a) 
LEVELS IN CONTROL GROUP 
Table 7 
LIPOPROTEIN(a) 
< 30 
mg /dl 
30-59 
mg /dl 
60-99 
mg / dl 
>100     
mg /dl 
NO OF CASES 22 2 1 0 
 
Fig 7  
CONTROL GROUP 
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DISTRIBUTION OF LIPOPROTEIN(a) IN MALES AND FEMALES 
IN STUDY GROUP 
Table 8 
SEX 
NO OF 
PERSONS 
LIPOPROTEIN(a) 
>30mg/dl 
NO.OF. MALES 23 20 
NO. OF. FEMALES 2 0 
Fig 8  
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DISTRIBUTION OF LIPOPROTEIN(a) IN MALES AND FEMALES 
IN CONTROL GROUP 
Table 9 
SEX NO. OF PERSONS 
LIPOPROTEIN(a)      
>30 mg/dl 
MALE 23 3 
FEMALE 2 0 
Fig 9  
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CONTROL GROUP 
23
2
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INCIDENCE OF RECURRENT STROKE IN STUDY GROUP 
Table 10 
 
RECURRENT STROKE MALE FEMALE 
NO OF CASES 4 0 
 
Fig 10  
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STATISTICAL ANALYSIS 
 
GROUP >30 mg/dl < 30 mg/dl TOTAL 
STUDY GROUP 20 5 25 
CONTROL GROUP 3 22 25 
TOTAL 23 27 50 
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Using chi-square, p value was derived.  It was found to be < 0.001, which is 
highly statistically significant. 
Hence the lipoprotein(a) levels noted in our study population of young 
ischemic stroke assume statistical significance.   
 
 
 
 
 
AGE AND LIPOPROTEIN(a) 
Analysis of study group 
  The highest lipoprotein(a) level noted in our study was 109 mg/dl.  It was 
observed in the age group of 21-25years.  The patient was 23years of age. 
The lowest lipoprotein(a) level of <10 mg/dl was noted  in 5 patients equally 
distributed in all the five age groups. 
 The mean lipoprotein(a) level in each group is  
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16-20 years 23 mg/dl 
21-25 years 59.5 mg/dl 
26-30 years 45.32 mg/dl 
31-35 years 40.38 mg/dl 
36-40 years 49.65 mg/dl 
The mean lipoprotein(a) was found to be the  highest in the age group of      
21-25 years with a level of 59.5 mg/dl.  This was entirely contributed by the highest 
level of 109 mg/dl observed in the study.  The mean lipoprotein(a) level was below 
the cut-off mark of 30 mg/dl, only in the age group of 16-20years.  All the other age 
group showed an increase in the mean lipoprotein(a) level.  
 
Analysis of Control Group 
The highest level of lipoprotein(a) in the control group was 63mg/dl. It was 
noted in the age-group of 26-30 years.   The patient was 27 years of age. 
The lowest level of <10 mg/dl was noted in three patients. 
The mean lipoprotein(a) of the control group in each age group is  
 16-20 Years 14.2 mg /dl 
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21-25 Years 17.4 mg /dl 
26-30 Years 30.89 mg /dl 
31-35 Years 18.33 mg /dl 
36-40 Years 26.18 mg /dl 
 
The mean lipoprotein(a) level of 26-30 years age group was slightly above the 
cut-off level of 30mg/dl.  The mean lipoprotein(a) of other age groups fell below the 
cut off level of 30mg/dl. 
 
 
 
 SEX DISTRIBUTION 
The study population comprised 23 males and two females, matched with the 
control group in a similar proportion. 
Lipoprotein(a) and sex 
  In study group 
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 Out of the 23 males with ischemic stroke, three did not show an increase in 
lipoprotein(a) level. The two female in the study population had levels of  less than 
10 mg /dl. 
 The mean lipoprotein(a) in male is 48.27 mg /dl. 
 The mean lipoprotein(a) in female is  less than 10 mg /dl. 
Lipoprotein(a) and sex 
In control Group 
 Out of the twenty three males included in the control group, only three had 
elevated lipoprotein(a) levels. Both the female had lipoprotein(a) levels less than 30 
mg/dl. 
 The mean lipoprotein(a) in male is 24.23 mg /dl. The mean lipoprotein(a) in 
female is 16 mg /dl. 
 
 
AGE DISTRIBUTION 
In Study Group 
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The study population included ischemic stroke patients aged forty years or less. 
The youngest of the study group aged 18 years and the eldest was 40 years of age.  
The mean age was 35years. 
Out of the 25 stroke patients included in the study, 10 fall into the age group of 
36-40 years.  The age group of 16-20 years and 21-25 years comprised 8% of the 
study population. 
This is consistent with the fact that as age increases, the risk of stroke increases 
and age is the single most important predictor of stroke. 
 
 
 
 
 
 
 
 
In Control Group 
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The control group of 25 individuals were age matched and sex matched.  The 
distribution of 25 control group population according to age group is similar to that of 
the study group. 
    
16-20 years 2 
21-25 years 2 
26-30 years 5 
31-35 years 6 
36-40 years 10 
 
The youngest of the control group was 16 years of age and the eldest was 40 
years of age.   
The mean age of the control group was 31.76 years and the median age 
calculated was 34 years.   
 
DISCUSSION 
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Analysis of lipoprotein(a) levels in young ischemic stroke patients 
  In the study group of 25 young ischemic stroke patients and the 25 age and sex-
matched controls, lipoprotein(a) levels were analysed.  In the study group, the 
lipoprotein(a) level was elevated in twenty of the twenty-five stroke patients.. The 
lipoprotein(a) levels ranged from less than 10 mg/dl to 109 mg/dl. The mean 
lipoprotein(a) level was higher than the cut off level of 30 mg/dl. 
 
Inference:  Lipoprotein(a) levels were elevated in young ischemic stroke. 
             The above inference of our study is supported by the studies of, 
1. Vavernova et al 1993, 99 
2. Peynert et al 1999,102 
3. Nagayama et al 1994,103 These studies have concluded that the levels of 
lipoprotein(a) is significantly raised in young ischemic stroke.
 
 
 
Lipoprotein(a) as an independent risk factor 
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This study is carried out in non-diabetic and non-hypertensive young stroke 
patients.  Even in young patients, next to age, hypertension and diabetes – the two 
conventional risk factors are the most important causes for ischemic stroke.   
Excluding these two risk factors in our study, gave us a chance to explore the 
newer risk factor-lipoprotein(a). Eliminating these two risk factors also made this 
study result much more reliable. The elevated lipoprotein(a) levels in our study group 
was statistically significant. 
Inference: Lipoprotein(a) is an independent risk factor in young ischemic stroke. 
            The study result is well supported by the studies of 
1. Zenker et al 1986, 3 
2. Nagayama et al 1994, 103
3. Atherosclerosis Risk In Communities (ARIC) study 1994.104 
All the above studies conclude that lipoprotein(a) is an independent risk factor 
and a predictor of stroke.     
 
 
 
 
 
     
56 
 
Levels of lipoprotein(a) in study and control population   
  The study group of young ischemic patients was compared with age and sex 
matched controls. Hence the two important confounding variables, age and sex were 
eliminated. The mean lipoprotein(a) in the study group was 20.84 mg/dl more than 
the control group.  
Eighty percentage of our study group (80%) and twelve percentage (12%) of 
our control group had elevated lipoprotein(a) levels. A p value of <0.001 was 
derived, denoting the statistical significance of such elevated lipoprotein(a) levels in 
study group. 
Inference: The levels of lipoprotein(a) was statistically higher in study group when 
compared with control group    
            This inference of our study is supported by the results of the studies of Peyner 
et al, 102   and Jurgens et al.100    
             Both these studies compared lipoprotein(a) levels of ischemic stroke patients 
with that of controls. They concluded that lipoprotein(a) levels are elevated 
significantly in study group .       
 
 
Lipoprotein(a) variation with age    
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           The highest level of lipoprotein(a) observed  in our study group was 109 
mg/dl. This level was noted in a 23 year old male.  The lowest level observed was  
less than10 mg/dl.  This was noted in five persons and equally distributed in each of 
the five age groups. 
             Lipoprotein(a) levels were elevated in four of the five age groups. The mean 
lipoprotein level was higher in the age group of 21-25 years. This was contributed by 
the highest level of lipoprotein(a).The mean lipoprotein(a) level did not vary much 
with age groups in our study population.    
             The highest lipoprotein(a) level of control group was  63 mg /dl and the 
lowest was less than 10 mg /dl. The highest level was noted in the 26-30 years age. 
The mean lipoprotein(a) noted in four of the five age groups in the control population 
did not show any elevation .  
Inference: Lipoprotein(a) does not vary with age. 
The studies of Jenner et al, 37 report that age and sex does not have any effect 
on lipoprotein(a) levels. Our study result is supported by the above reference. 
 
 
 
To correlate lipoprotein(a) levels in men and women
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   Our study population comprised of twenty three males and two females. The 
two females in the study group did not show any increase in lipoprotein(a) level.   
Only two of the 23 males in the study group did not have increased lipoprotein(a) 
level.  In our study, the mean lipoprotein(a) levels in males was  higher  than in 
females. In the control group also, the mean lipoprotein(a) levels of males was higher 
than that of females. However, the females comprised only 8 % of study population. 
The sample size was too small to note that this difference is significant. 
Inference: Lipoprotein(a) levels in males is higher than in females. The reliability of 
this association is weak and statistical significance could not be noted. 
Relationship of lipoprotein(a) levels to recurrent ischemic stroke 
         Four of our stroke patients had history of stroke previously. All of them 
had ischemic infarcts. All the four patients had elevated lipoprotein(a) levels. Two of 
them had levels greater than 100 mg/dl. Both were non smokers. And in both of them 
no other risk factors were present. Thus, elevated lipoprotein levels could be taken as a 
predictor of recurrent stroke. Studies associating lipoprotein(a) levels to recurrent 
ischemic stroke are lacking. This offers us scope for further studies to assess whether 
elevated lipoprotein(a) is a predictor of recurrent strtoke. 
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CONCLUSION 
 
1. The levels of lipoprotein(a) are elevated  in young ischemic stroke. 
2. Lipoprotein(a) is an independent risk factor for young ischemic stroke. 
3. Lipoprotein(a) levels are higher in young ischemic stroke patients than in                    
controls.  This is statistically significant. 
4. Lipoprotein(a) does not vary with age. 
5. Men have higher levels of lipoprotein(a) compared to women.  Larger 
sample of women is needed to assign statistical significance to this result. 
6. Lipoprotein(a) levels could well be a predictor of recurrent stroke. Further 
studies are needed. 
7. Our study results correlate well with studies, that support lipoprotein(a) as 
a possible  risk factor in young stroke.   
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LIPOPROTEIN(a) LEVELS IN YOUNG ISCHEMIC STROKE 
 
 
 
 
 
Name                                                      Age                            Sex   
 
      
Occupation 
 IP NO 
Address 
 
D.O.A 
D.O.D 
 
Diagnosis 
 
Presenting complaints 
  
Past history                   HT                    DM                 CAD          TIA 
                                       Valvular Heart Disease 
                                       Renal disease                Malignancy       Rheumatoid Arthritis 
                                      Hyperlipidemia 
 
Personal history             Smoker                Alcohol  
 
Physical examination    BP 
                                        PR                                                 Weight       Height 
                                        BMI 
                                        Carotids 
                                        Vessel wall thickening 
                                        CNS findings 
 
Investigations 
 
Hb gm%         TC                       DC                                      PCV               ESR 
Urine               Albumin             Sugar                                  Deposits 
Blood sugar                                Blood Urea                         Serum Creatinine 
ECG    
Serum Lipoprotein(a) mg/dl 
HIV                                               VDRL 
CT findings 
 
Outcome 
 
 
 The prevalence rates of stroke from various major epidemiological studies in 
India 
Table A 
Zone Place 
Rural /  
Urban 
Year Population
Crude 
Prevalence 
rate per 
100,000 
Age 
Adjusted 
Rate Per  
100,000 
Rohtak, Haryana, Urban 1971-74 79,046 44 - 
North 
 
Kuthar valley, 
Kashmir, 
Rural 1986 63,645 143 244* 
Mumbai, among 
the Parsis 
Urban 1985 14,010 842 424* 
West 
Mumbai Urban 1997 145,456 220 - 
Malda, West 
Bengal 
Rural 1989-90 37,286 126 - 
Baruipur,  
West Bengal 
Rural 1992-93 20,842 147 - East 
Kolkata Urban 1998-99 50,291 147 334** 
Vellore Rural 1969-71 258,576 57 84 
Gowribidinur, 
Karnataka  
Rural 1982-84 57,660 52 - 
Bangalore Rural 1993-95 51,055 165 262 
South 
Bangalore  Rural 1993-95 51,502 136 - 
 
*Age standardized to 1960 US population; ** Age standardized to 1996 US 
population; Year of US population for age-standardization not known 
 
 
 
  
The Annual Incidence Rates of stroke from various epidemiological studies in 
India 
 
Table B 
 
Place Rural / urban Year Population 
Annual 
incidence 
rate per 
100,000 
Age 
adjusted 
annual 
incidence 
rate per 
100,000 
Vellore Rural 1969-71 258,576 13 - 
Kolkata Urban 1998-99 50,291 36 105* 
Baruipur,  
West -     
Bengal 
Rural 1993-98 20,842 124 262** 
 
*Age adjusted to 1996 US Population; **Age-adjusted to 1990 US Population 
 
 
 
 
 
 
 
S.NO 
Name 
 Ip.No 
Age         Sex Complaints HT DM Smoker Alcoholism
Family 
h/o stroke 
Recurrent 
stroke 
BMI PR
BP in 
mmHg 
CVS 
RBS 
mg/dl 
ECG 
LP(a) 
mg/dl 
CT BRAIN DIAGNOSIS OUTCOME 
1 
Mr. Neelakandan 
904661 
23  M
Weakness     
Lft. UL+LL 
No No No No Yes Yes, same side 21.55 74 130/80 S1 S2 + 70 Normal 109 
Rt Frontoparietal 
infarct  
CVA /   
 Rt. Hemispherical    
stroke 
Discharged 
2 
Mr. Packirisamy 
912423 
40      M
Weakness     
Rt. UL+LL 
aphasia 
No No
Yes   
5/day 
Yes  
1/week 
No No 22.33 68 124/86 S1 S2 + 82 Normal < 10.00 Lft.MCA Infarct 
CVA/ 
Lft.hemispherical 
stroke 
Discharged 
3 
Mr. Arumugam 
906218 
40          M
Weakness     
Rt. UL+LL 
No No
Yes   
10/day 
No No No 23.83 78 110/80 S1 S2 + 86 Normal 55.10 
Lft.MCA infarct; no 
mass effect 
CVA /                
Lft. Hemispherical  
stroke 
Discharged 
4 
Miss. Rassiya 
912678 
19           F
Weakness Rt. 
UL+LL 
No No No No No No 20.13 80 116/84 S1 S2+ 84 Normal < 10.00 Lft. Cortical infarct 
CVA /                
Lft. Hemispherical  
stroke 
Discharged 
5 
Mr. Muruganandham 
926378 
27          M
Weakness    
Lft. UL+LL 
No No
Yes  
4/day 
No No No 25.6 78 126/80 S1 S2 + 94 Normal 37.40 
Rt. Temporal basal 
ganglia and 
paraventricular region 
infarct 
CVA /                
Rt. Hemispherical  
stroke 
Discharged 
6 
Mr. Ram 
945127 
33         M
Weakness    
Lft. UL+LL 
No No
Yes  
8/day 
Yes  
2/week 
No No 23.01 68 110/86 S1 S2+ 92 Normal < 10.00
Rt. Internal capsule 
region infarct 
CVA /               
Rt. Hemispherical  
stroke 
Dischargedd 
7 
Miss. Umarani 
940978 
22              F
Weakness     
Rt. UL+LL 
No No No No No No 19.72 82 110/80 S1 S2 + 88 Normal < 10.00
Lft. Parieto temporal 
infarct 
CVA /                
Lft. Hemispherical  
Ischemic stroke 
Discharged 
8 
Mr. Sekar 
919767 
30              M
Weakness     
Rt. UL+LL 
No No No No No No 26.56 70 116/78 S1 S2 + 98 Normal 62.20
Normal study             
No evidence of 
hemorraghe 
CVA /                
Lacunar infarct   Discharged 
9 
Mr. Sekar 
944396 
38         M
Weakness    
Lft. UL+LL 
No No
Yes  
5/day 
Once/a 
week 
No No 25.50 82 138/74 S1 S2+ 118 Normal 47.90
Hypodensity in the 
region of internal 
capsule Rt. Side 
CVA /               
Rt. Hemispherical   
stroke 
Discharged 
10 
Mr. Sekar 
934643 
37          M
Weakness    
Lft. UL+LL 
No No No
2 drinks/ 
week 
No No 25.00 90 118/68 S1 S2+ 100 Normal 40.20
Hypodensity in the 
region of Rt. Internal 
capsule 
CVA / ischemic   
Rt. Hemispherical  
stroke  
Discharged 
11 
Mr. Murugesan  
945611 
37  M
Weakness    
Lft. UL+LL No No No No No No 25.63 88 134/70 S1 S2+  98 Normal 30.90 Rt. MCA infarct 
CVA /                
Rt. Hemispherical  
Ischemic stroke 
Discharged 
12 
Mr. Arputharaj  
947816 
34          M
Weakness     
Rt. UL+LL 
No No
8 Beedi / 
day  
No No No 21.63 74 110/80 S1 S2+ 88 Normal 52.70 Lft. MCA infarct  
Lft. Hemispherical  
stroke 
Discharged 
13 
Mr. Vadivel        
947816 
40     M
Weakness     
Rt. UL+LL 
No No No No No Yes, same side 20.76 86 124/80 S1 S2+ 74 Normal 108.00
Lft. Internal capsular & 
basal ganglia infarction 
Lft. Hemispherical  
stroke 
Discharged 
14 
Mr. Senthil Kumar 
950149 
35           M
Weakness    
Lft. UL+LL 
No No No No No No 27.71 80 110/80 S1 S2+ 114 Normal 46 Rt. MCA infarct 
Rt. Hemispherical  
stroke 
Dischargedd 
15 
Mr. Vengadesan 
953882 
30              M
Weakness    
Lft. UL+LL 
No No No No No No 23.52 78 130/80 S1 S2+ 110 Normal 55
Rt. Parieto occipital 
infarct 
Rt. Hemispherical  
stroke 
Discharged 
16 
Mr. Ravi              
953631 
35           M
Weakness        
Rt. UL+LL 
No No No No No No 21.40 72 124/86 S1 S2+ 128 Normal 40.0 Lft. Watershed infarct 
Lft. Hemispherical 
  stroke 
Discharged 
17 
Mr. Jeyaseelan 
955860 
30              M
Weakness     
Rt. UL+LL 
No No No No No No 22.14 80 130/80 S1 S2+ 110 Normal < 10.00
Lft. Internal capsular 
infarct 
Lft. Hemispherical  
stroke 
Discharged 
18 
Mr. Palaiya          
956966 
30              M
Weakness     
Rt. UL+LL 
No No No No No No 19.53 64/mt 120/80
S1 S2+ 
head 
126 Normal 62.00
Lft. MCA territory 
infarct 
Lft. Hemispherical 
   stroke 
Discharged 
19 
Mr. Chandrasekhar 
957361 
18  M
Weakness     
Rt. UL+LL 
No  No No No No No 34.39 74 130/82 S1 S2 + 70 Normal 36.00 Lft. MCA infarct 
Lft. Hemispherical 
stroke 
 
At request 
Discharged 
  
 
 
20 
 
Mr. Sundaramoorthy 
957472 
 
40 
 
M 
 
Weakness      
Rt. UL+LL 
 
No 
 
No 
 
5 
cigar/day 
 
NO 
 
NO 
 
Yes, same side 
 
34.37  
 
82 
 
130/86 
 
S1 S2+
 
 
111 
 
Normal 
 
48.00 
 
Lft. Internal capsular 
infarct  
 
CVA /                
Lft. Hemispherical  
Ischemic stroke 
Discharged 
21 
Mr. Boominathan 
936180 
35          M
Weakness    
Lft. UL+LL 
No No
5cigarette 
/day 
NO NO NO 28.60 86 130/86 S1 S2 + 98  Normal 38.60 
Rt. MCA territory 
infarct 
CVA /               
Rt. Hemispherical    
Ischemic Stroke 
Discharged 
22 
Mr. Karunanidhi  
961735  
35          M
Weakness      
Rt. UL+LL of 
aphasia 
No No
5cigarette 
/day      
10 years 
NO NO NO 25.28 84 110/80 S1 S2+  91 Normal 55.00 Lft. MCA infarct 
CVA /                
Lft. Hemispherical  
Ischemic stroke 
Discharged 
23 
Mr. Kuzhandaisamy 
935642  
40     M
Weakness      
Rt. UL+LL 
No No NO NO NO Yes, same side 23.10 88 120/84 S1 S2+ 100 Normal 48.30
Lft. MCA infarct Old 
Lft. Frontal infarct 
CVA /                
Lft. Hemispherical  
& current stroke 
Discharged 
24 
Mr. Paneerselvam 
927145 
40  M
Weakness    
Lft. UL+LL 
 No No NO NO NO NO 26.56 84 130/86 S1 S2+ 86 Normal 62.10 Rt. MCA infarct 
CVA /               
Rt. Hemispherical    
Ischemic  Stroke  
Discharged 
25 
Mr. Anbazhagan 
937652 
37             M
Weakness      
Rt. UL+LL 
No No
1pack 
/day         
5 years 
NO NO NO 25.00 84 110/86 S1 S2+ 114 Normal 46.00
Lft. Internal capsular 
infarct 
CVA /                
Lft. Hemispherical  
Ischemic stroke 
Dischargedd 
26 
Mr.Prabhakar  
957214 
29           M
Abd pain loose 
stools 
No No No No No No 20.06 88 120/80 S1 S2+ 110  Normal  24.12 No Gastroenteritis 
Discharged 
after 6 days 
27 
Mr.Satish  
957190 
21 M Fever x 2 days No No No No No No 26.98 90 110/80 S1 S2 126 Normal  12.80 No Viral fever 
Discharged 
after 7 days 
28 
Mr.Azhagapa Devar 
955996 
34           M
Weakness of all 
four limbs 
No No No No No No 30.04 78 130/80 S1 S2+  114 Normal  <10 No 
Hypokalemic 
periodic paralysis 
Discharged 
after 2 days 
29 
Mrs.Devi  
965072 
23            F Viral fever No No No No No No 29.05 80 114/80 S1 S2 + 90 Normal  22 No Viral fever 
Discharged 
after 2 days 
30 
Mr. Ganesan  
955926 
31            M Seizures No No No No No No 30.22 78 110/80 S1 S2+  86 Normal 19 No Seizure disorder 
Discharged 
after 2 days 
31 
Mr.Prabhakaran 
947510 
16            M Viral fever No No No No No No 25.56 74 100/70 S1 S2+ 78 Normal  18.4 No Viral fever 
Discharged 
after 5 days 
32 
Mr. Ravi              
947446 
40             M
Weakness of all 
four limbs 
No No No No No No 27.16 88 110/80 S1 S2+ 96 Normal 21 No
 Hypokalemic 
periodic paralysis 
Discharged 
after 2 days 
 
33 
Miss.Sandhya 
960075 
16                F
Increased 
fatiguability 
No No No No No No 26.02 78 110/80 S1 S2+ 88 Normal <10 No Nutritional anaemia
Discharged 
after 4 days 
34 
Mr. Jamal Mohammed 
926926  
27      M
100ml of 
hemetemein 
No No
10 cig/ 
day 
2-3 
times/week 
No No 27.68 86 110/86 S1 S2+ 100 Normal 18.74 No Minor UGI bleed 
Discharged 
after 3 days  
35 
Mr. Shanmugavel 
927835 
27  M
Consumption 
of rat killer 
power  
No No  No  No  No  No  28.30 94 110/80 S1 S2+  118 Normal 63 No Rat killer poisoning 
Discharged 
after 3 days 
36 
Mr. Rameshkumar 
929164   
29  M
Increased 
fatigability 
No No 15cig/day No  No No  18.93 78 110/80 S1 S2+  126 Normal 27 No Nutritional anemia 
Discharged 
after 6 days 
37 
Mr.Ramachandran 
923004 
27 M Fever 1 week No No 5cig/day No No No 21.48 88 116/70 S1 S2+  108 Normal 21.6 No Viral fever 
Discharged 
after 2 days 
38 
Mr. Ramasamy  
923039 
31         M Chest pain No No 10cig/day
2-3 drink/ 
week 
No No 24.2 78 120/84 S1 S2+  98 Normal  10.8 No 
Non cardiac chest 
pain 
Discharged 
after 1 days 
39 
Mr. Chandrasekhar 
926011  
32       M
Consumption 
of unknown 
poisoning 
No No 20cig/day
4-5 drink/ 
week 
No No 18.62 74 116/80 S1 S2 + 104 Normal  24.9 No Unknown poisoning 
Discharged 
after 3 days 
                     
40 Mr. Mohan  
958999 
36 M One episode of 
seizure 
No         No 12cig/day No No No 21.77 74 114/80 S1 S2+  104 Normal  57.0 No Seizure disorder  Discharged 
after 5 days 
41 
Mr.Illavarasan 
 959059 
37            M Unknown bite No No No No No No 29.00 82 116/70 S1 S2+ 98 Normal  18.2 No Unknown bite 
Discharged 
after 2 days 
42 
Mr. Ponnusamy  
960995  
37            M Snake bite No No 6cig/day No No No 24.22 84 128/80 S1 S2+  110 Normal  25.2 No 
Non poisonous 
snake bite 
Discharged 
after 3 days 
43 
Mr. Rajkumar 
 959892  
38 M Snake bite No No 3cig/day No  No  No  23.52 90 118/80 S1 S2+  94 Normal  26.1 No 
Non poisonous 
snake bite  
Discharged 
after 4 days 
44 
Mr. Michael  
959803 
40 M Fever 4 days No  No 5 cig/day No No No 20.67 92 110/80 S1 S2+ 120 Normal  19.9 No Viral fever 
Discharged 
after 4 days 
45 
Mr. Siva  
956300 
36    M
Epigastric 
pain*2days 
No  No  
20 
cig/day 
Consumes 
5 
drink/week 
No No 21.67 98 116/84 S1 S2 + 116 Normal  <10 No Gastritis  
Discharged 
after 2 days 
46 
Mr.Murugan 
961380 
37 M Fever 1 week No No No No No No 28.44 106 120/80 S1 S2+  118 Normal  21.8 No Viral fever  
Discharged 
after 4 days  
47 
Mr.Pandiyan  
960275 
36            M Unknown bite No No No No No No 22.49 104 118/76 S1 S2 + 120 Normal  50.6 No Unknown bite 
Discharged 
after 2 days  
48 
Mr.Sivaraman  
959327 
38               M
Fever breath 
Lessness 
No No No No No No 26.56 94 110/80 S1 S2+ 120 Normal 12 No
Rt lower lobe 
pneumonia  
Discharged 
after 6 days 
49 
Mr.Muthuvel  
959325 
35               M
Cough with 
expectoration 
No No 10cig/day No No No 21.26 110 114/82 S1 S2+ 114 Normal 20.3 No
Pulmonary 
tuberculosis 
Discharged 
after 4 days 
50 
Mr.Dhanapal 
 958940  
35 M Unknown bite  No No No No No No 21.25 88  120/80 S1 S2+ 96   Normal 25 No Unknown bite
Discharged 
after 4 days 
  
